Lupin’s stock soared 5% after HSBC reaffirmed its ‘Buy’ rating, setting a target price of ₹2,565 per share. As of 10:01 AM, the shares were trading 5.35% higher at Rs 2,133.60.
HSBC noted that Lupin’s Q3 performance was operationally in line with expectations. The company anticipates full-year EBITDA margins in the range of 23-23.5%, based on its 9MFY25 results. This margin expansion reflects Lupin’s focus on cost efficiency and profitability.
The brokerage remains bullish on Lupin’s long-term prospects, citing key product launches in the US and a growing complex generics pipeline as major growth drivers. HSBC has projected an impressive 26.5% EPS CAGR over FY24-27, reinforcing its optimistic outlook.
With a robust product pipeline, steady US market expansion, and a strong earnings trajectory, Lupin continues to be a compelling investment opportunity. Investors are closely watching the stock as it moves towards HSBC’s ambitious price target.
Lupin’s stock opened at ₹2,051.15 and reached a high of ₹2,140.00 during the trading session. The stock’s 52-week high stands at ₹2,402.90, while the 52-week low is ₹1,493.30.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
